News
Addition of ublituximab to ibrutinib improves response in r/r CLL
Ibrutinib, the Bruton’s tyrosine kinase (BTK) inhibitor, has transformed the treatment landscape for patients with relapsed or refractory (r/r)...
News
CAR T cells elicit durable, potent responses in kids with EM relapse of ALL
CHICAGO—Outcomes for pediatric patients with relapsed acute lymphoblastic leukemia (ALL) are dismal, with the probability of event-free survival...
News
Study confirms increased adiposity in HSCT survivors
ORLANDO, FL—A recently conducted study confirms that survivors of hematopoietic stem cell transplant (HSCT) have increased body fat mass and lower...
News
Study advances precision opioid dosing for mucositis
ORLANDO, FL—A pilot study to determine the burden of mucositis in pediatric patients undergoing hematopoietic stem cell transplant (HSCT) showed...
News
Single dose of ZA pre-transplant prevents bone loss
ORLANDO, FL—A single, 4 mg-dose of the bisphosphonate zoledronic acid (ZA) prior to allogeneic hematopoietic stem cell transplant (HSCT) prevents...
News
Inpatient palliative care improves QOL for HSCT patients
ORLANDO, FL—New research shows that patients who received inpatient palliative care while undergoing hematopoietic stem cell transplant (HSCT)...
News
All cases of CRS are not created equal
2016 ASH Annual Meeting SAN DIEGO—Investigators have found that life-threatening cytokine release syndrome (CRS) and its symptoms are due to the...
News
HU trial to prevent stroke in SCA feasible in Nigeria
© Todd Buchanan 2016 SAN DIEGO—High rates of recruitment (90%), enrollment (92%), and adherence to study drug and follow-up visits have confirmed...
News
Old drug, new tricks possible in MM
SAN DIEGO—An antiretroviral drug used to treat the human immunodeficiency virus (HIV) may find a role in the treatment of multiple myeloma (MM)...
News
MM patients with t(11;14) benefit from venetoclax
SAN DIEGO—Venetoclax, the oral BCL-2 inhibitor approved by the US Food and Drug Administration to treat chronic lymphocytic leukemia (CLL)...
News
Combined checkpoint blockade promising in HL
SAN DIEGO—Immune checkpoint blockade with nivolumab plus ipilimumab has shown promise in treating hematologic malignancies, particularly classical...
News
Ruxolitinib may prevent CRS after CAR T-cell therapy
Photo courtesy of NCI SAN DIEGO—A novel xenograft model of acute myeloid leukemia (AML) demonstrated that the JAK/STAT inhibitor ruxolitinib can...
News
MDS patients with mutated IDH2 benefit from enasidenib
Photo courtesy of ASH SAN DIEGO—Daily treatment with enasidenib monotherapy in patients with mutated IDH2-positive myelodysplastic syndromes (MDS...
News
CAR met primary endpoint at interim analysis in DLBCL
2016 ASH Annual Meeting SAN DIEGO—The chimeric antigen receptor (CAR) T-cell therapy KTE-C19 has met its primary endpoint at the pre-specified...
News
How old is too old to be on a kids’ protocol for ALL?
Photo by Bill Branson SAN DIEGO—In recent years, pediatric or pediatric-inspired protocols have become the preferred treatment approach for...